In short
Utreloxastat, also known as PTC857, is a promising drug currently being studied in clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). This article explores the ongoing research into Utreloxastat's potential efficacy, safety, and tolerability in adults with ALS, providing insights into the drug's development and its possible impact on disease progression.
At a glance
- Drug Name
- Utreloxastat (PTC857)
- Condition Studied
- Amyotrophic Lateral Sclerosis (ALS)
- Trial Phase
- Phase 2
- Study Design
- Randomized, Double-Blind, Placebo-Controlled
- Primary Objective
- Evaluate efficacy in reducing ALS disease progression
- Dosage
- 250 mg twice daily (oral solution)
- Trial Duration
- Up to 160 weeks (including extension periods)
- Key Assessments
- ALSFRS-R, survival, respiratory function, motor function, quality of life
- Biomarker
- Plasma neurofilament light chain (NfL)
What is UTRELOXASTAT?
UTRELOXASTAT, also known as PTC857, is a new investigational drug being developed by PTC Therapeutics, Inc. for the treatment of Amyotrophic Lateral Sclerosis (ALS). It is currently undergoing clinical trials to assess its effectiveness and safety in patients with ALS. UTRELOXASTAT is also known by other names, including EPI 857 and 2,3,5-trimethyl-6-nonyl-2,5-cyclohexadiene-1,4-dione.
What Medical Condition Does UTRELOXASTAT Treat?
UTRELOXASTAT is being developed to treat Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive neurological disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. It is often referred to as Lou Gehrig's disease. ALS causes muscle weakness and atrophy throughout the body, eventually affecting a person's ability to speak, eat, move, and breathe.
How Does UTRELOXASTAT Work?
While the exact mechanism of action of UTRELOXASTAT is not explicitly stated in the provided information, it is being studied for its potential to reduce disease progression in ALS patients. The drug is being investigated for its effects on various aspects of ALS, including:
- Slowing down the progression of the disease
- Improving respiratory function
- Enhancing motor/limb and bulbar function (which affects speech and swallowing)
- Potentially improving survival rates
- Improving quality of life for ALS patients
Current Clinical Trial Information
UTRELOXASTAT is currently being studied in a Phase 2 clinical trial called CARDINALS (PTC857-CNS-001-ALS). This trial is designed to assess the efficacy, safety, tolerability, pharmacokinetics (how the drug moves through the body), and biomarker effects of PTC857 in adult subjects with ALS. The study is structured in three parts:
- Treatment Period (Part A): Participants are randomly assigned to receive either UTRELOXASTAT (250 mg twice daily) or a matching placebo for 24 weeks.
- Long-Term Extension Period (Part B): Participants continue treatment for an additional 28 weeks, with all subjects receiving open-label UTRELOXASTAT.
- Continued Long-Term Extension Period (Part C): Participants can continue treatment for an additional 108 weeks, receiving open-label UTRELOXASTAT.
Dosage and Administration
In the clinical trial, UTRELOXASTAT is being administered as an oral solution at a dose of 250 mg twice daily. The maximum daily dose being studied is 500 mg. It's important to note that this dosage is specific to the clinical trial and may change based on the results of the study.
Who Can Participate in the Clinical Trial?
The clinical trial has specific eligibility criteria for participants. Some key inclusion criteria include:
- Adults aged 18-80 years
- Diagnosed with ALS within the past 24 months
- Have a total ALS Functional Rating Scale-Revised (ALSFRS-R) score of at least 34
- Have relatively preserved respiratory function
There are also several exclusion criteria, such as pregnancy, certain medical conditions, and use of specific medications.
Potential Benefits of UTRELOXASTAT
While the effectiveness of UTRELOXASTAT is still being studied, the clinical trial aims to evaluate several potential benefits:
- Reduction in disease progression
- Improvement in respiratory function
- Enhancement of motor/limb and bulbar function
- Potential increase in survival rates
- Improvement in quality of life
- Reduction in plasma neurofilament light chain (NfL) activity, a biomarker of neuronal damage
Safety Considerations
As with any investigational drug, the safety of UTRELOXASTAT is being closely monitored in the clinical trial. The study is assessing:
- The number and severity of treatment-emergent adverse events
- Changes in clinical laboratory tests
- Physical examination results
- Vital signs
- Suicide risk (using the Columbia-Suicide Severity Rating Scale)
- Electrocardiogram (ECG) results
It's important to note that as an investigational drug, UTRELOXASTAT is not yet approved for general use, and its safety and efficacy are still being evaluated. Patients interested in this treatment should consult with their healthcare providers about the possibility of participating in clinical trials or other treatment options for ALS.